Revolutionizing Cancer Diagnostics

Revolutionizing Cancer Diagnostics
Published on: September 1, 2020
Author: Fann Li

VolitionRx Ltd. (NYSE AMERICAN: VNRX) is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Corporate Highlights:

  • Epigenetics healthcare company with a suite of easy to use blood-based cancer tests under development
  • We believe that simple to use blood tests are the best way to achieve improved levels of compliance (>80%)
  • Broad intellectual property portfolio, including 53 granted patents to date worldwide
  • Proof of concept data reported with plate-based assays in Lung, Colorectal Cancer, Blood Cancer
  • Texas-based Volition Veterinary subsidiary to develop and commercialize Nu.Q Vet
  • Acquired epigenetic reagents company Octamer GmbH, now Volition Germany

For more information, visit company’s website:

Register now to listen to VolitionRx’s presentation at the GCFF Virtual Conference on September 10th at 9am – 9:20am PST (12pm – 12:20pm EST)!

Corporate Speaker

Scott Powell

Executive Vice President & Head of Investor Relations, VolitionRx Limited
Chief Financial Officer, Volition America, Inc.

Scott has more than 20 years of experience in the U.S. capital markets, investment banking, investor relations and corporate communication. Based in New York City, he directs a comprehensive capital markets program and investor relations strategy for Volition. His role includes strategic interactions with institutional investors, analysts, investment banks, and the financial media. Scott has served as Head of Investor Relations for four public companies, including Volition, and worked for several years as an investment banker in New York City. He earned his Bachelor of Science in Business Administration from Bryant University in Smithfield, RI, his Master of Arts and Doctor of Philosophy degrees from Brown University in Providence, RI, and his Certificate in Business from Columbia University in New York City.

GCFF Virtual Conference – Investing in Innovation

September 10th, 2020 Thursday

8:30am – 1:30pm PST (11:30am – 4:30 EST)

Covering the healthcare, technology, fintech and cannabis sectors the GCFF Virtual Conference – Investing in Innovation will provide its participants with access to exciting investment opportunities that are at the cusp of value growth. The bilingual online event will feature 12 public and private company presentations and will broadcasted in both English and Mandarin Chinese channels. Register for our virtual event today!


Healthcare Life Science